Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Anticipates Vyvanse Approval In “Next Month Or Two”

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm is considering a marketing partner and aims to replace its ADHD treatment Adderall XR with Vyvanse.

You may also be interested in...



Shire Anticipates Vyvanse Approval “Any Day”

Firm also announces plan to acquire Vyvanse partner New River Pharmaceuticals for $2.6 billion in cash.

Shire Anticipates Vyvanse Approval “Any Day”

Firm also announces plan to acquire Vyvanse partner New River Pharmaceuticals for $2.6 billion in cash.

Teva Generic Versions Of Focalin Clear FDA With 180-Day Exclusivity

The approval includes 2.5 mg, 5 mg and 10 mg formulations of dexmethylphenidate tabs for ADHD.

Related Content

Topics

UsernamePublicRestriction

Register

PS065104

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel